全文获取类型
收费全文 | 100篇 |
免费 | 10篇 |
专业分类
基础医学 | 18篇 |
口腔科学 | 3篇 |
临床医学 | 8篇 |
内科学 | 58篇 |
神经病学 | 1篇 |
外科学 | 1篇 |
预防医学 | 4篇 |
眼科学 | 2篇 |
药学 | 2篇 |
肿瘤学 | 13篇 |
出版年
2022年 | 1篇 |
2019年 | 3篇 |
2018年 | 3篇 |
2017年 | 1篇 |
2016年 | 1篇 |
2015年 | 1篇 |
2014年 | 2篇 |
2013年 | 3篇 |
2012年 | 5篇 |
2011年 | 3篇 |
2010年 | 2篇 |
2009年 | 3篇 |
2008年 | 7篇 |
2007年 | 7篇 |
2006年 | 7篇 |
2005年 | 3篇 |
2004年 | 7篇 |
2003年 | 5篇 |
2002年 | 8篇 |
2001年 | 13篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1997年 | 5篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1982年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有110条查询结果,搜索用时 15 毫秒
1.
2.
Bashir Q Khan H Orlowski RZ Amjad AI Shah N Parmar S Wei W Rondon G Weber DM Wang M Thomas SK Shah JJ Qureshi SR Dinh YT Popat U Anderlini P Hosing C Giralt S Champlin RE Qazilbash MH 《American journal of hematology》2012,87(3):272-276
A total of 149 patients with multiple myeloma (MM) who received allogeneic hematopoietic stem cell transplantation (allo-HCT) with myeloablative (MAC; n = 38) or reduced-intensity conditioning (RIC; n = 110) regimens at MD Anderson Cancer Center were evaluated. Of the total, 120 (81%) patients had relapsed or had refractory disease. Median age of MM patients was 50 (28-70) years with a followup time of 28.5 (3-164) months. The 100-day and 5-year treatment related mortality (TRM) rates were 17% and 47%, respectively. TRM was significantly lower with RIC regimens (13%) vs. 29% for MAC at 100 days (P = 0.012). The cumulative incidence of Grade II-IV acute graft-versus-host disease (GVHD) was 35% and chronic GVHD was 46%. PFS and OS at 5 years were 15% and 21%, respectively. In multivariate analysis, allo-HCT for primary remission consolidation was associated with longer PFS (HR 0.35; 95% CI, 0.18-0.67) and OS (HR 0.29; 95% CI 0.15-0.55), while absence of high-risk cytogenetics was associated with longer PFS only (HR 0.59; 95% CI 0.37-0.95). We observe that TRM has decreased with the use of RIC regimens, and long-term disease control can be expected in a subset of MM patients undergoing allo-HCT. Further studies should be conducted in carefully designed clinical trials in this patient population. 相似文献
3.
Apisarnthanarax N Donato M Körbling M Couriel D Gajewski J Giralt S Khouri I Hosing C Champlin R Duvic M Anderlini P 《Bone marrow transplantation》2003,31(6):459-465
We conducted a retrospective analysis of all allogeneic stem cell transplantation (ASCT) patients started on extracorporeal photopheresis (ECP) for the management of steroid-dependent (SD) or steroid-refractory (SR) cutaneous chronic graft-versus-host disease (cGVHD) following ASCT during a 36-month period (9/98-8/01). Only SD or SR patients who were treated by ECP after day 100 and who received at least 4 weeks of ECP were considered evaluable for this analysis. Out of 64 ASCT patients reviewed, 32 patients met the inclusion criteria. All 32 patients had been previously treated with systemic corticosteroids with 11 (34%) being SR and 21 (66%) SD. Cutaneous cGVHD was extensive in 28 patients (88%) and was accompanied by visceral (hepatic, gastrointestinal) cGVHD in 23 patients (72%). The 32 evaluated patients had received a median of three prior therapies before ECP, most commonly systemic corticosteroids, tacrolimus, and mycophenolate mofetil. Patients received a median of 36 ECP sessions (range 12-98) over a median of 5.3 months (range 1-28), with a median of six sessions per month. The complete response (CR) rate was 22% (n=7) and the partial response rate was 34% (n=11). In all, 28 patients were on systemic corticosteroid therapy at ECP initiation and 18 patients achieved 50% dose reduction while on ECP, yielding a 64% steroid-sparing response rate. Of seven CRs, five are ongoing. A total of 11 (34%) patients have died after ECP, with all cases due to visceral cGVHD or cGVHD-related infectious complications. All 21 surviving patients remain on at least some immunosuppressive cGVHD therapy (including ECP in eight). Overall, ECP displays a substantial response rate and, in particular, steroid-sparing activity in SR/SD extensive cutaneous cGVHD. However, most patients continue to require at least some chronic therapy and cGVHD-related morbidity and mortality remain high. 相似文献
4.
PURPOSE: To describe a 61-year-old healthy peripheral blood progenitor cell (PBPC) donor who developed marginal keratitis and mild uveitis on the third day after receiving daily recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; sargramostim) to mobilize PBPCs for allogeneic transplantation. METHODS: Interventional case report. RESULTS: The keratitis was treated with topical administration of 1% prednisolone acetate solution and resolved within 24 hours. The topical steroid dose was tapered and ultimately discontinued without recurrence of keratitis. CONCLUSION: Healthy PBPC donors receiving rhG-CSF or rhGM-CSF should be monitored for ocular complications, particularly marginal keratitis and uveitis. 相似文献
5.
6.
David F. Stroncek Bronwen E. Shaw Brent R. Logan Deidre M. Kiefer Bipin N. Savani Paolo Anderlini Christopher N. Bredeson Peiman Hematti Siddhartha Ganguly Miguel Angel Diaz Hisham Abdel-Azim Ibrahim Ahmed Dipnarine Maharaj Matthew Seftel Amer Beitinjaneh Sachiko Seo Jean A. Yared Joerg Halter Michael A. Pulsipher 《Biology of blood and marrow transplantation》2018,24(1):175-184
Little is known about the experiences of individuals donating peripheral blood stem cells (PBSCs) or marrow for a second time. To study this, unrelated donors making a second donation through the National Marrow Donor Program between 2004 and 2013 were evaluated. Experiences of second-time donors giving marrow (n?=?118: first donation was PBSC in 76 and marrow in 42) were compared with those making only 1 marrow donation (n?=?5829). Experiences of second-time donors giving PBSCs (n?=?602) (first donation was PBSCs in 362; marrow in 240) were compared to first-time PBSC donors (n?=?16,095). For donors giving a second PBSC or marrow donation there were no significant differences in maximum skeletal pain, maximum symptoms measured by an established modified toxicity criteria, and recovery time compared with those who donated only once. Notably, the yield of marrow nucleated cells and PBSC CD34+ cells with second donations was less. As previously noted with single first-time donations, female (PBSCs and marrow) and obese donors (PBSCs) had higher skeletal pain and/or toxicity with a second donation. PBSC donors who experienced high levels of pain or toxicity with the first donation also experienced high levels of these symptoms with their second donation and slower recovery times. In conclusion, for most donors second donation experiences were similar to first donation experiences, but CD34+ yields were less. Knowledge of the donor's first experience and stem cell yields may help centers decide whether second donations are appropriate and institute measures to improve donor experiences. 相似文献
7.
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy 总被引:30,自引:48,他引:30
Giralt Sergio; Estey Elihu; Albitar Maher; van Besien Koen; Rondon Gabriela; Anderlini Paolo; O'Brien Susan; Khouri Issa; Gajewski James; Mehra Rakesh; Claxton David; Andersson Borje; Beran Miloslav; Przepiorka Donna; Koller Charles; Kornblau Steve; Korbling Martin; Keating Michael; Kantarjian Hagop; Champlin Richard 《Blood》1997,89(12):4531-4536
8.
Paolo Anderlini Donna Przepiorka David Seong Richard Champlin & Martin Körbling 《British journal of haematology》1996,94(1):155-158
Thirteen normal adult donors underwent daily leukapheresis for peripheral blood progenitor cell collection for allografting beginning on day 4 or 5 of G-CSF mobilization (12 μg/kg/d). They had complete blood counts performed 7–10 d after the completion of the procedure. A reduction in the total leucocyte count below baseline levels, accounted for by a decrease in the absolute neutrophil (ANC) and lymphocyte counts, was noted. Neutropenia (ANC < 1.5 × 109 /l) occurred in two (15%) of the donors. The lowest ANC observed was 0.6 × 109 /l. The neutropenia was asymptomatic and resolved on follow-up evaluation. 相似文献
9.
Anderlini P Saliba R Acholonu S Okoroji GJ Donato M Giralt S Andersson B Ueno NT Khouri I De Lima M Hosing C Cohen A Ippoliti C Romaguera J Rodriguez MA Pro B Fayad L Goy A Younes A Champlin RE 《Bone marrow transplantation》2005,35(10):943-951
A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling (n=20) or a matched unrelated donor (n=20). The median age was 31 years (range 18-58). Disease status at allo-SCT was refractory relapse (n=14) or sensitive relapse (n=26). The conditioning regimens were fludarabine-cyclophosphamide+/-antithymocyte globulin (n=14), a less intensive regimen, and fludarabine-melphalan (FM) (n=26), a more intensive one. The two groups had similar prognostic factors. The median time to neutrophil recovery (ie absolute neutrophil count >/=500/microl) was 12 days (range 10-24). The median time to platelet recovery (ie platelet count >/=20 000/microl) was 17 days (range 7-132). Day 100 and cumulative (18-month) transplant-related mortalities (TRMs) were 5 and 22%. Twenty-four patients (60%) are alive (14 in complete remission or complete remission, unconfirmed/uncertain) with a median follow-up of 13 months (4-78). In all, 16 patients expired (TRM n=8, disease progression n=8). FM patients had better overall survival (73 vs 39% at 18 months; P=0.03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P=0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival. 相似文献
10.